Emerging Drug Developer: Immune Design

Immune Design

Boom times in the vaccine industry have helped breed a new generation of vaccine development start-ups, and Seattle-based Immune Design believes it can be one of the most successful. The biotech company combines research undertaken by Steven Reed on small molecules and the viral vector work of Nobel laureate David Baltimore in a company that is advancing a new approach to adjuvants and vaccines.  

And as we see in so many biotech start-ups, a venture capital player helped put it all together. Article

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.